As LAG-3 expression increased on TILs including CD8+ TPEX in the tumors after anti-metabolite chemotherapy, we sought to determine if adding anti-(a)LAG-3 with anti-(a)PD-1 ICB would improve anti-tumor immunity after chemotherapy. Here, LAG3 is linked to neoplasm.